Systematic Review of In Vitro Antimicrobial Susceptibility Testing for Bacillus anthracis, 1947–2019. (17th October 2022)

• Record Type: Journal Article
• Authors: Maxson, Tucker; Kongphet-Tran, Thiphasone; Mongkolrattanothai, Thitipong; Travis, Tatiana; Hendricks, Katherine; Parker, Corinne; McLaughlin, Heather P; Bugrysheva, Julia; Ambrosio, Frank; Michel, Pierre; Cherney, Blake; Lascols, Christine; Sue, David
• Is Part Of: Clinical infectious diseases. Volume 75(2022)Supplement 3
• Page Start: S373
• Page End: S378
• Publication Date: 2022-10-17
• Subjects: Bacillus anthracis -- antimicrobial resistance -- susceptibility testing -- bioterrorism -- preparedness; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciac520
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: Bacillus anthracis, the causative agent of anthrax, is a high-consequence bacterial pathogen that occurs naturally in many parts of the world and is considered an agent of biowarfare or bioterrorism. Understanding antimicrobial susceptibility profiles of B. anthracis isolates is foundational to treating naturally occurring outbreaks and to public health preparedness in the event of an intentional release. In this systematic review, we searched the peer-reviewed literature for all publications detailing antimicrobial susceptibility testing of B. anthracis . Within the set of discovered articles, we collated a subset of publications detailing susceptibility testing that followed standardized protocols for Food and Drug Administration–approved, commercially available antimicrobials. We analyzed the findings from the discovered articles, including the reported minimal inhibitory concentrations. Across the literature, most B. anthracis isolates were reported as susceptible to current first-line antimicrobials recommended for postexposure prophylaxis and treatment. The data presented for potential alternative antimicrobials will be of use if significant resistance to first-line antimicrobials arises, the strain is bioengineered, or first-line antimicrobials are not tolerated or available. Abstract : The data presented for potential alternative antimicrobials will be of use if significant resistance to first-line antimicrobials arises, the strain is bioengineered, or if first-line antimicrobials are not tolerated or available.